September 02, 2025 New Bruton’s Tyrosine Kinase Inhibitor Improves Platelet Response The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy. Conexiant
August 27, 2025 Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma The ASCO Post
August 22, 2025 Evidence of Potential Cure With Single CAR T-Cell Infusion for Some Patients With Multiple Myeloma The ASCO Post
August 22, 2025 Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach The ASCO Post
August 27, 2025 Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma The ASCO Post
August 18, 2025 Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL The ASCO Post
August 15, 2025 Experimental Approach to Graft-vs-Host Disease Prophylaxis Offers Alternative to Standard Regimen The ASCO Post
September 02, 2025 Introducing the Ahmed ClearPath® ST: Evolving Design for Evolving Needs in Glaucoma Surgery The Ophthalmologist
September 02, 2025 APP CROSS: A Novel Scoring System to Evaluate Advanced Practice Provider Clinical Rotation Requests in Oncology JADPRO
September 02, 2025 Understanding the Role and Clinical Management of Bridging Therapy During CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma JADPRO
August 29, 2025 How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting The ASCO Post